Back
Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Journal article

Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.

  • Edwards SE Department of Health Care Management, Berlin University of Technology, Berlin, Germany.
  • Morel CM Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • 2019-12-19
Published in:
  • Expert review of pharmacoeconomics & outcomes research. - 2019
Antibiotics
antimicrobial resistance
incentives
research and development (R&D)
Anti-Bacterial Agents
Commerce
Drug Development
Drug Industry
Drug Resistance, Bacterial
Humans
Public Health
Research Support as Topic
English Introduction: Governments need to do far more to help curb the emergence and transmission of antibiotic resistance and help protect the efficacy of any new antibiotics that come to the market. Industry is an important stakeholder that must be brought on-board such efforts given its influence on the direction and scale of antibiotic sales. Financial incentives supporting industry R&D of novel antibiotics should structurally remove the drivers of superfluous sales and encourage access to newer antibiotics where infections are otherwise resistant to treatment. Indeed, the use of public money provides an important opportunity to prioritize these public health goals within market structures such that we both adequately reward industry for their efforts and prolong antibiotic efficacy for as long as possible.Areas covered: This work discusses possible financial 'pull' incentives that fully delink the reward paid to the developer from unit sales, examining their primary advantages and limitations.Expert opinion: Pharmaceutical companies need to be rewarded generously for their efforts to develop new, badly needed antibiotics. But the current marketplace does not provide a sustained financial lure and its reliance on unit-sales for profitability jeopardizes the efficacy of antibiotics both new and old. Fully delinked models can make antibiotic R&D more financially appealing and create a market environment that is far less threatening to public health.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/53311
Statistics
Document views: 20 File downloads: